The estimated Net Worth of Stephen George Dilly is at least $37 Milión dollars as of 8 September 2023. Dr Dilly owns over 58,479 units of Sierra Oncology Inc stock worth over $24,133,901 and over the last 15 years he sold SRRA stock worth over $12,066,208. In addition, he makes $778,945 as Pres a CEO & Director at Sierra Oncology Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr D SRRA stock SEC Form 4 insiders trading
Dr has made over 16 trades of the Sierra Oncology Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 58,479 units of SRRA stock worth $101,169 on 8 September 2023.
The largest trade he's ever made was exercising 165,374 units of Sierra Oncology Inc stock on 1 June 2018 worth over $499,429. On average, Dr trades about 21,870 units every 59 days since 2010. As of 8 September 2023 he still owns at least 438,878 units of Sierra Oncology Inc stock.
You can see the complete history of Dr Dilly stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Stephen George Dilly M.B.B.S, Ph.D. biography
Dr. Stephen George Dilly M.B.B.S, Ph.D. is the Pres, CEO & Director at Sierra Oncology Inc.
What is the salary of Dr D?
As the Pres a CEO & Director of Sierra Oncology Inc, the total compensation of Dr D at Sierra Oncology Inc is $778,945. There are 3 executives at Sierra Oncology Inc getting paid more, with Barbara Klencke having the highest compensation of $971,397.
How old is Dr D?
Dr D is 61, he's been the Pres a CEO & Director of Sierra Oncology Inc since . There are 6 older and 11 younger executives at Sierra Oncology Inc. The oldest executive at Sierra Oncology Inc is Robert Pelzer, 66, who is the Independent Chairman of the Board.
What's Dr D's mailing address?
Stephen's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Insiders trading at Sierra Oncology Inc
Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth a James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.
What does Sierra Oncology Inc do?
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
What does Sierra Oncology Inc's logo look like?
Complete history of Dr Dilly stock trades at Aimmune Therapeutics Inc, Codexis, Sangamo Therapeutics Inc a Sierra Oncology Inc
Sierra Oncology Inc executives and stock owners
Sierra Oncology Inc executives and other stock owners filed with the SEC include:
-
Barbara Klencke,
Chief Development Officer -
Mark Kowalski,
Chief Medical Officer -
Sukhi Jagpal,
Chief Financial Officer -
Dr. Stephen George Dilly M.B.B.S, Ph.D.,
Pres, CEO & Director -
Dr. Barbara J. Klencke M.D.,
Chief Medical Officer -
Dr. Mark M. Kowalski M.D., Ph.D.,
Chief of Research & Early Devel. -
Robert Pelzer,
Independent Chairman of the Board -
James Smith,
Vice President Corporate Affairs -
Andrew Sinclair,
Independent Director -
Josh Richardson,
Independent Director -
Jeffrey Cooper,
Independent Director -
Mona Ashiya,
Independent Director -
Andrew Allen,
Independent Director -
Gaurav Aggarwal,
Independent Director -
Craig Collard,
Director -
William Turner,
Chief Regulatory and Technical Operations Officer -
Kevin Norrett,
Chief Business Officer -
Christina Thomson,
General Counsel -
Stephen Dilly,
President, Chief Executive Officer, Director -
Kevin Norrett M.B.A., M.S.,
Chief Bus. Officer -
William D. Turner,
Chief Regulatory & Technical Operations Officer -
Christina Thomson J.D., M.S.,
Gen. Counsel, Chief Compliance Officer & Sec. -
Sukhi Jagpal CA, CPA, CBV, MBA,
Chief Financial Officer -
Daniel Estes,
Director -
James N Topper,
Director -
Nicholas Glover,
CEO and President -
Nicole Onetto,
Director -
Tran Nguyen,
Director -
Donald R Parfet,
Director -
Angie You,
Chief Bus. & Strat. Officer -
Capital Partners Iii, Llc L...,
-
Christian Hassig,
Chief Scientific Officer -
Opportunity, Llc Vivo Oppor...,
-
Advisors Llcorbimed Capital...,
-
Opportunity, Llc Vivo Oppor...,
-
Advisors Llc Orbi Med Capit...,
-
Georgia Erbez,
Director -
Christy J. Oliger,
Director -
Llp Abingworth,
10% owner -
Mary Christina Thomson,
General Counsel -
Advisors Llc Orbi Med Capit...,